Results 191 to 200 of about 1,637,423 (248)

Leucine alleviates cytokine storm syndrome by regulating macrophage polarization via the mTORC1/LXRα signaling pathway. [PDF]

Elife
Yan H, Liu Y, Li X, Yu B, He J, Mao X, Yu J, Huang Z, Luo Y, Luo J, Wu A, Chen D.   +11 more
europepmc   +1 more source

Dapagliflozin Attenuates NKCC2 Protein Expression and Alleviates Diabetic Kidney Disease in Salt Loaded‐Hypertensive Diabetic Db/Db Mice

FASEB BioAdvances, Volume 8, Issue 10, October 2026.
In salt‐loaded, hypertensive diabetic db/db mice with diabetic kidney disease, dapagliflozin lowered blood pressure and reduced tubular and glomerular injury. Mechanistically, dapagliflozin increased cullin E3 ligase abundance, promoting degradation of NKCC2.
Zenab Shahzad, Niharika Bala, Arooba Illyas, Amir Kazory, Indra Chandrasekar, Abdel A. Alli   +5 more
wiley   +1 more source

The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease

British Journal of Pharmacology, Volume 183, Issue 19, Page 5732-5751, October 2026.
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam, James Harris, Jürgen Bernhagen, Antony Vinh, Katrina M. Mirabito Colafella   +4 more
wiley   +1 more source

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

European Journal of Haematology, Volume 117, Issue 4, Page 922-935, October 2026.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio, Antonio José Martinez‐Mellado, Jonathan Kiwitt‐Cárdenas, José G. Clavel, Bartolomé García‐Perez, Pedro Castro, Maribel Diaz‐Ricart, Andrés Carrillo‐Alcaraz, Amparo López‐Bernús, Enrique Bernal Morell, Aychel Roura, Sonia Marín, Francisco‐José Ruiz‐López, Elena Solana‐Martinez, Domingo Martinez‐Baño, Carlos L. Albacete Moreno, Enriqueta Andreu Soler, Adrián Tellez Santoyo, Sara Fernández Méndez, Jose A. Noguera Velasco, Iria Cebreiros Lopez, Andrés Parrilla, Alberto Espuny‐Miró, David García‐Bernal, Miguel Blanquer, Andrés Sánchez‐Salinas, Francisca Iniesta, Cristina Hernandez Garcia, Manuel Muro, Alfredo Minguela Puras, Antonio Moreno‐Docón, Alberto M. Torres‐Cantero, Maria Munoz Garcia, Manuel Serrano, Massimo Iacobelli, Carmelo Carlo‐Stella, Lee‐Jen Wei, Paul G. Richardson, José M. Moraleda   +38 more
wiley   +1 more source

Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
Schematic overview of superantigen‐mediated antitumor immune responses and immune suppression within the tumor microenvironment. (1) Antigen‐presenting cells activate T cells through MHC‐II/TCR interactions resulting in the production of cytokines (2) The pro‐inflammatory cytokines released by activated immune cells stimulate downstream immune ...
Urooj Yousaf Virk, Hafiza Aasia Malik, Muneera Anwer, Jennifer Wilson, Md. Sifat Rahi, Ming Q. Wei   +5 more
wiley   +1 more source

Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. [PDF]

Eur Respir J, 2020
Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS.   +4 more
europepmc   +1 more source

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? [PDF]

Autoimmun Rev, 2020
Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, Rimoldi S, Galimberti L, Sarzi-Puttini P, Ridolfo AL.   +9 more
europepmc   +1 more source

The Inversion of IL-6 Levels in Relation to C-Reactive Protein as the Marker for Cytokine Storm Syndrome in COVID-19

, 2022
Filho SPdMM, Martins FS, Giroldi PJ, Melo RHe, Oliveira ELd, Santos ABd, Medeiros DCO, Basano SdA, Lopes JA, Chaves YO, Camargo LMA, Zuliane JP, Nogueira PA.   +12 more
europepmc   +1 more source

Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients? [PDF]

Ren Fail, 2020
Chen G, Zhou Y, Ma J, Xia P, Qin Y, Li X.   +5 more
europepmc   +1 more source